Business Context and Reporting Period
This Form 8-K was filed by DSS, Inc. on July 21, 2025, reporting a material definitive agreement entered into on the same date. The filing concerns a debt restructuring transaction with Impact Biomedical Inc.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or overall liquidity for DSS, Inc. The only specific financial data disclosed relates to the debt conversion transaction:
- Debt Principal: $12,000,000 (Original Note issued March 31, 2023).
- Interest Rate: WSJ Prime + 0.5% (as amended January 18, 2024).
- Consideration Received: 31,939,778 shares of Impact Biomedical Inc. common stock.
- Transaction Scope: Settlement includes all outstanding debt, interest, and financial/operational support extended between June 21, 2025, and the closing date.
Material Changes
The primary material change is the conversion of a $12 million revolving promissory note into equity. This transaction results in the full and final satisfaction of all amounts owed to DSS by Impact Biomedical Inc., removing the receivable from DSS's balance sheet in exchange for an equity position in the borrower.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclaimer that the summary is qualified by the full text of the agreement. The transaction is presented as a completed settlement of obligations.
Investor Verification Checklist
- Verify the fair market value of the 31,939,778 Impact Biomedical Inc. shares received to assess potential impairment or gain on the transaction.
- Confirm the trading status and liquidity of the Impact Biomedical Inc. shares (noted as "freely tradeable" in the filing).
- Review the full text of the Debt Conversion Agreement (Exhibit 10.1) for any retained rights, covenants, or contingent liabilities.
- Assess the impact of this equity swap on DSS's current portfolio concentration and exposure to the biotechnology sector.